News
AUTL
4.520
-5.83%
-0.280
Recent 9.9% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 165% over 1 year
Simply Wall St · 14h ago
Weekly Report: what happened at AUTL last week (0408-0412)?
Weekly Report · 4d ago
Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook
Needham maintained a Buy rating on Autolus Therapeutics (AUTL) with a price target of $9.00. Gil Blum has given his Buy rating due to a combination of factors surrounding the potential of the company. The company’s focus on engineering precise, controllable, tailored T-cell therapies may address significant unmet needs in the treatment of cancer.
TipRanks · 04/12 10:06
GLYC, APLD and AUTL are among after hour movers
Seeking Alpha · 04/11 21:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Ontrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. Ocuphire Pharma stock rose 7.82% and Lyell Immunopharma stock rose by 7.5%. Motus GI Hldgs stock declined by 32.6% during the after- market session.
Benzinga · 04/11 20:31
Autolus Therapeutics Is Maintained at Buy by Truist Securities
Dow Jones · 04/09 17:51
Autolus Therapeutics Price Target Raised to $11.00/Share From $10.00 by Truist Securities
Dow Jones · 04/09 17:51
Truist Securities Maintains Buy on Autolus Therapeutics, Raises Price Target to $11
Benzinga · 04/09 17:41
Weekly Report: what happened at AUTL last week (0401-0405)?
Weekly Report · 04/08 09:12
AUTOLUS THERAPEUTICS PLC - US MARKETING APPLICATION IS UNDER REVIEW PDUFA DATE OF NOV 16
Reuters · 04/02 11:05
Autolus Therapeutics Announces Board Leadership Changes
TipRanks · 04/01 11:22
AUTOLUS THERAPEUTICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS
Reuters · 04/01 11:00
AUTOLUS THERAPEUTICS PLC: APPOINTMENT OF MIKE BONNEY AS CHAIRMAN OF BOARD
Reuters · 04/01 11:00
Weekly Report: what happened at AUTL last week (0325-0329)?
Weekly Report · 04/01 09:12
Autolus Therapeutics Plc Files For Resale Of Up To 33.33M Shares By The Selling Securityholder
Benzinga · 03/28 20:22
Weekly Report: what happened at AUTL last week (0318-0322)?
Weekly Report · 03/25 09:12
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Etao International Co (NASDAQ:ETAO) shares increased by 180.5% to $0.4 during Wednesday's pre-market session. The company's market cap stands at $40.4 million. Jaguar Health stock rose 42.96% and SCWorx stock increased by 14.08% in the same session.
Benzinga · 03/20 13:05
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company has an average price target of $9.0. 4 analysts have expressed a variety of opinions on AutolusTherapeutics over the past quarter. The 12-month price targets assessed by analysts have increased by 9.09% to $8.25.
Benzinga · 03/18 16:01
Autolus Therapeutics Is Maintained at Buy by Truist Securities
Dow Jones · 03/18 13:56
Autolus Therapeutics Price Target Raised to $10.00/Share From $9.00 by Truist Securities
Dow Jones · 03/18 13:56
More
Webull provides a variety of real-time AUTL stock news. You can receive the latest news about AUTOLUS THERAPEUTICS PLC through multiple platforms. This information may help you make smarter investment decisions.
About AUTL
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.